FDA Cancels Advisory-Committee Meeting on Merck Surgery Drug

FDA Cancels Advisory-Committee Meeting on Merck Surgery Drug

Despite a positive recommendation from an advisory panel, sugammadex was rejected by the FDA in 2008 because of concerns about possible allergic reactions and increased risks of bleeding when it was used with certain blood-thinning drugs.

3
Like
Save

Comments

Write a comment

*